Onartuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade

Description of Onartuzumab Biosimilar - Anti-MET, RCCP2 mAb - Research Grade

Introduction to Onartuzumab Biosimilar – Anti-MET, RCCP2 mAb

Onartuzumab Biosimilar, also known as Anti-MET, RCCP2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancers. This biosimilar is designed to target the MET receptor, which is a key player in cancer progression and metastasis. In this article, we will explore the structure, activity, and potential applications of Onartuzumab Biosimilar in cancer treatment.

Structure of Onartuzumab Biosimilar

Onartuzumab Biosimilar belongs to the class of monoclonal antibodies, which are proteins that are designed to bind to specific targets in the body. It is a biosimilar of the original drug Onartuzumab, which was developed by Genentech and has shown promising results in clinical trials for certain types of cancer. The biosimilar version is produced by a different company, using similar manufacturing processes and quality control measures to ensure its similarity to the original drug.

The structure of Onartuzumab Biosimilar is based on the variable region of the original Onartuzumab antibody, which is responsible for binding to its target. This region is combined with a constant region, which is responsible for the antibody’s stability and effector functions. The resulting biosimilar has a similar structure to the original drug, making it a suitable alternative for cancer treatment.

Activity of Onartuzumab Biosimilar

Onartuzumab Biosimilar is designed to target the MET receptor, which is a protein found on the surface of cancer cells. MET is a receptor for hepatocyte growth factor (HGF), a protein that promotes cell growth and survival. In cancer, MET is often overexpressed, leading to uncontrolled cell growth and metastasis. By targeting MET, Onartuzumab Biosimilar can block the signaling pathway that promotes cancer cell growth and spread.

In preclinical studies, Onartuzumab Biosimilar has shown promising results in inhibiting the growth and spread of cancer cells. It has also been shown to enhance the effects of other cancer treatments, such as chemotherapy and radiation therapy. This makes it a potential candidate for combination therapy in cancer treatment.

Applications of Onartuzumab Biosimilar

Onartuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC), gastric cancer, and glioblastoma. In a phase II clinical trial for NSCLC, Onartuzumab Biosimilar showed promising results in combination with chemotherapy, leading to longer progression-free survival in patients with high levels of MET expression.

In addition to its potential use as a standalone therapy, Onartuzumab Biosimilar also has the potential to be used in combination with other targeted therapies. For example, it has been shown to enhance the effects of EGFR inhibitors in lung cancer cells with MET amplification.

Conclusion

Onartuzumab Biosimilar – Anti-MET, RCCP2 mAb is a promising monoclonal antibody that targets the MET receptor in cancer cells. Its structure is based on the original drug Onartuzumab, and it has shown similar activity in preclinical studies. In clinical trials, it has shown potential as a standalone therapy and in combination with other treatments. With ongoing research and development, Onartuzumab Biosimilar has the potential to become an important therapeutic option for cancer patients.

SDS-PAGE for Onartuzumab Biosimilar - Anti-MET, RCCP2 mAb

Onartuzumab Biosimilar - Anti-MET, RCCP2 mAb, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.